Now showing items 1-4 of 4

    • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. 

      Alam, S Munir; Boyd, SD; Cai, Fangping; Chen, S; Chen, Y; Cohen, M; Du, X; ... (45 authors) (Nature, 2013-04-25)
      Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details ...
    • Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV 

      Alam, S Munir; Bailer, RT; Buzby, AP; Denny, Thomas Norton; Ferrari, Guido; Fischer, W; Foulds, KE; ... (32 authors) (Nature, 2014-01-01)
      A major challenge for the development of a highly effective AIDS vaccine is the identification of mechanisms of protective immunity. To address this question, we used a nonhuman primate challenge model with simian ...
    • Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. 

      Alam, S Munir; Bailer, RT; Buzby, AP; Denny, Thomas Norton; Ferrari, Guido; Fischer, W; Foulds, KE; ... (32 authors) (Nature, 2014-01-23)
      A major challenge for the development of a highly effective AIDS vaccine is the identification of mechanisms of protective immunity. To address this question, we used a nonhuman primate challenge model with simian ...
    • Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. 

      Arthos, J; Bewley, CA; Bonsignori, Mattia; Boyington, JC; Burton, DR; Carrico, C; Chuang, G-Y; ... (47 authors) (Nature, 2011-11-23)
      Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity ...